Clinical Trial

Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the adult population aged 18 to 59 years without prior exposure to either arbovirus.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07 -> 2027-07 2026-07-17
minor Completion pushed: 2026-10 -> 2027-10 2026-07-17
Trial Details
NCT Number NCT06973772
Lead Sponsor Butantan Institute
Conditions Dengue, Chikungunya
Enrollment 900 participants
Start Date 2027-03-31
Primary Completion 2027-07 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-16